(Q33211747)

24 July 2017

title

Retrospective review of modafinil use for cerebral palsy (English)

1 reference

24 July 2017

1 reference

1 reference

Daniel L Hurst

1

1 reference

24 July 2017

Walter A Lajara-Nanson

series ordinal

2

1 reference

24 July 2017

Pradeep Dinakar

series ordinal

3

1 reference

24 July 2017

Randolph B Schiffer

series ordinal

4

1 reference

24 July 2017

publication date

1 December 2004

1 reference

Journal of Child Neurology

24 July 2017

published in

1 reference

24 July 2017

volume

19

1 reference

24 July 2017

issue

12

1 reference

24 July 2017

page(s)

948-951

1 reference

Use of modafinil in spastic cerebral palsy

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

Fatigue and declines in cognitive functioning in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

Risks and benefits of drugs used in the management of the hyperactive child

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

Methylphenidate and growth in hyperactive children. A controlled withdrawal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F08830738040190120701

10.1177/08830738040190120701

21 January 2018

Identifiers

DOI

1 reference

24 July 2017

1 reference